#HFSA2025
“You often learn from when science goes the opposite direction from what you expect,” said presenter David Berg, MD. The next question to answer is what role GDF-15 plays in heart failure. #HFSA2025 #CardioSky
October 1, 2025 at 1:13 PM
6 DAYS LEFT 🚨 Share your research with the #heartfailure community!

#HFSA2025 is the perfect place to put a spotlight on important research being conducted by researchers at all career levels and disciplines.

Submit your science by March 17th! hfsa.org/asm/submitti... #CardioSky
March 11, 2025 at 7:59 PM
#HFSA2025 Early Bird Registration is now open! Here's how you can claim the lowest prices of the year:

✅ Become an HFSA member
✅ Register before June 30 to claim the early bird discount
✅ Save $100 when you register for both ASM 2025 and the HFSA Devices in HF Meeting

hfsa.org/asm/registra...
June 10, 2025 at 3:55 PM
Ronald Witteles, MD presented on outcomes of vutrisiran monotherapy (vs placebo) in HELIOS-B with and without censoring tafamidis drop ins

#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
#HFSA2025 is just around the corner. Let’s exchange ideas on advancing heart failure care and see firsthand how Murj transforms fragmented cardiac device data from a burden into a strategic asset.

📅 September 26–29
📍 Booth 332 | Minneapolis
🤝 Book time to exchange ideas with our team bit.ly/45XhV18
September 18, 2025 at 5:38 PM
Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with #DCM https://bit.ly/4mE3vcM

#HFSA2025 #JACC #cvGenetics @jimjanuzzi.bsky.social
September 29, 2025 at 3:33 PM
Efficacy of vutrisiran in HELIOS-B by baseline health status (KCCQ) - consistent effects across the different categories analyzed

#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Come see us at #THT2025 - Booth #16! Learn more about submitting your science for publication in JCF-Intersections, get signed up for the latest HFSA Devices in Heart Failure Meeting news, and pick up some #HFSA2025 swag! @jcardfail.bsky.social
February 11, 2025 at 5:40 PM
At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF.

Watch now:
Vericiguat Improves HFrEF Regardless of Background Therapy, With Justin Ezekowitz, MD | HCPLive
Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.
www.hcplive.com
October 18, 2025 at 2:00 PM
🚨 #HFSA2025 SimPub alert!

The Heart Failure Society America’s 2025 Annual Scientific Meeting kicks off today, and JCF has 12 simultaneous publications releasing during the meeting!
September 26, 2025 at 11:15 PM
Continues acoramidis reduced ACM/CVH from the parent study to the OLE portion at Month 42

#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Disappointingly, a growth differentiation factor 15 neutralizer not only failed to improve functional outcomes in heart failure but was associated with harm in a trial that was terminated early. #HFSA2025
https://www.medpagetoday.com/meetingcoverage/hfsa/117753
Ponsegromab Crashes Out in Frailer Heart Failure Patients
GDF-15 suppression of no help, in fact increased HF risk, systemic inflammation
www.medpagetoday.com
October 4, 2025 at 3:25 PM
Thank you to Ahmad Masri, MD, for his live updates on emerging and potentially practice-changing clinical data on advances in the treatment of #ATTR-CM from #HFSA2025.

Check out this thread for highlights.

#MedIQHFSA2025
September 29, 2025 at 4:27 PM
“The time-sensitive nature of transthyretin cardiomyopathy is something that has been on many people’s minds, but I think this is the first piece of evidence that should push us forward,” said Ahmad Masri, MD at #HFSA2025. #CardioSky
October 1, 2025 at 7:22 PM
The first plenary session at #HFSA2025 is about to begin and all of my coverage will be on ⁦‪@tctmd.bsky.social!‬⁩ Who else is here and what are you looking forward to at the meeting?
September 27, 2025 at 1:54 PM
As the @hfsa.bsky.social Annual Scientific Meeting 2025 comes to a close, here are the final #HFSA2025 SimPubs, out now in the Journal of Cardiac Failure. 🚨

🧵👇
September 28, 2025 at 10:39 PM
Data from ATTRibute-CM on acoramidis potentially preventing the progression of conduction disease as part of ATTR-CM presented at #HFSA2025

#MedIQHFSA2025
September 29, 2025 at 4:27 PM
CLOSING SOON❗

The ASM 2025 session proposal submission window closes tonight! Scientific Sessions make up the core of the meeting's program, delivering the most innovative, ground-breaking science from across the heart failure field.

Submit yours: hfsa.org/asm/session-...

#HFSA2025 #CardioSky
February 3, 2025 at 7:41 PM
We presented exploratory data from ATTRibute-CM looking at all events - CVM and recurrent CVH - which show early and sustained effect of acoramidis throughout the study.

#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
Emily Martin presented on correlation of Tc-99m p5+14 in cardiac amyloidosis with clinical markers

#HFSA2025
#MedIQHFSA2025
September 29, 2025 at 4:27 PM
We’re excited to announce 2024’s Jay N. Cohn New Investigator Award winner Alvaro Delgado and runner-up Ameesh Isath, MD! If you are a young trainee/investigator, submit your research for #HFSA2025 for a chance to win an investigator award >> hfsa.org/asm/submitti... #CardioSky #HeartFailure
February 20, 2025 at 8:11 PM
We’re heading to #HFSA2025. Murj is shaping the future of cardiac device care—helping clinics move beyond fragmented data and legacy workflows to a modern, cloud-based platform.
September 2, 2025 at 7:21 PM
You're in luck 🍀 Less than 24 hours to submit your science for #HFSA2025!

Don't miss your chance to present your abstract to colleagues at the HFSA Annual Scientific Meeting! Your important research deserves to be seen.

Submit your general abstract: hfsa.org/asm/submitti...
March 17, 2025 at 6:15 PM
Large dataset on V122I both homozygous and heterozygous from the VA presented at #HFSA2025

#MedIQHFSA2025
September 29, 2025 at 4:27 PM
During #HFSA2025, we sat down with Barry Borlaug, MD, to discuss his prespecified analysis of sex differences with tirzepatide for obesity-related heart failure, based on results from the phase 3 SUMMIT trial.

Watch now:
Tirzepatide Affects Men and Women with HFpEF Equally, With Barry Borlaug, MD | HCPLive
A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.
www.hcplive.com
October 11, 2025 at 2:00 PM